+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Model for end-stage liver disease score predicts adverse events related to ventricular assist device therapy



Model for end-stage liver disease score predicts adverse events related to ventricular assist device therapy



Annals of Thoracic Surgery 93(5): 1541-7; Discussion 1547-8



The Model for End-stage Liver Disease (MELD) score is a marker of multisystem organ dysfunction. It has been used to predict outcomes in patients undergoing hepatic and nonhepatic interventions. End-stage heart disease exhibits a varying degree of multiorgan dysfunction, which impacts the adverse events related to ventricular assist device (VAD) therapy. Our aim for the present study was to investigate the value of MELD score in predicting adverse events related with VAD therapy. Data were collected on demographics, clinical characteristics, MELD score; Interagency Registry for Mechanically Assisted Circulatory Support-defined VAD adverse events within the first 6 months, and survival from VAD recipients (n=286; from 1996 to 2009). Univariable, multivariable, and Cox regression analyses were performed using SAS software (SAS Institute, Cary, NC). The mean MELD score was 14.4±5.9. Actuarial incidence of infections, bleeding events, and cardiovascular dysfunction at 6 months was 65.4%, 52.1%, and 45.6%, respectively. Multivariable Cox proportional hazards model (controlling for gender, type of device, diagnosis, intention to treat, urgency, and inotropic use) confirmed that MELD score predicted mortality, respiratory, and renal dysfunction at 6 months (p<0.01). Preoperative MELD score is predictive of mortality, respiratory, and renal dysfunction at 6 months after controlling for gender, type of device, diagnosis, intention to treat, urgency, and inotropic use. The MELD score may be used as a quantitative tool to assess the adverse events associated with VAD therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036373661

Download citation: RISBibTeXText

PMID: 22480391

DOI: 10.1016/j.athoracsur.2012.02.008


Related references

Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 121(2): 214-220, 2010

Predictive value of the model for end-stage liver disease score in patients undergoing left ventricular assist device implantation. Asaio Journal 59(1): 57-62, 2013

Model for end-stage liver disease predicts right ventricular failure in patients with left ventricular assist devices. Journal of Artificial Organs 19(1): 21-28, 2016

Predictive Value of Models for End-Stage Liver Disease Score in Patients With Pulsatile Flow POLVAD MEV Left Ventricular Assist Device Support. Transplantation Proceedings 50(7): 2075-2079, 2018

Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility-related adverse events. European Journal of Heart Failure 2018, 2018

Implication of Preoperative Existence of Atrial Fibrillation on Hemocompatibility-Related Adverse Events During Left Ventricular Assist Device Support. Circulation Journal 2019, 2019

Haemocompatibility-related adverse events are associated with a non-optimal haemodynamic profile during continuous-flow left ventricular assist device support: why it matters. European Journal of Heart Failure 2019, 2019

Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Annals of Thoracic Surgery 86(4): 1227-34; Discussion 1234-5, 2008

Attenuation in peripheral endothelial function after continuous flow left ventricular assist device therapy is associated with cardiovascular adverse events. Circulation Journal 79(4): 770-777, 2015

Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score. International Journal of Clinical and Experimental Medicine 7(12): 5751-5757, 2015

Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) Scoring System to Predict Outcomes in Patients Who Undergo Left Ventricular Assist Device Implantation. Annals of Thoracic Surgery 106(2): 513-519, 2018

Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. Journal of Heart and Lung Transplantation 31(6): 601-610, 2013

The Combination of Tricuspid Annular Plane Systolic Excursion and HeartMate Risk Score Predicts Right Ventricular Failure After Left Ventricular Assist Device Implantation. Asaio Journal 2018, 2018

Impact of adverse events on ventricular assist device outcomes. Current Heart Failure Reports 10(1): 89-100, 2013

Relationship between model for end-stage liver disease score and left ventricular function in patients with end-stage liver disease. Hepatobiliary and Pancreatic Diseases International 10(1): 50-54, 2011